NeoChord
NeoChord is a privately held medical device company developing beating-heart mitral valve repair systems. Its CE-marked DS1000 and investigational NeXuS transcatheter platform deliver artificial chordae under echo guidance to treat degenerative mitral regurgitation at cardiac surgery centers.
- Company typePrivate
- Founded2007
- HeadquartersSaint Louis Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeoChord does
NeoChord, Inc. is a privately held medical device company founded in 2007 and headquartered in Maple Grove, Minnesota. The company develops devices that enable mitral valve repair to be performed on a beating heart, addressing degenerative mitral valve regurgitation (MR) without requiring cardiopulmonary bypass or open sternotomy. Its flagship product, the NeoChord Artificial Chordae Delivery System (Model DS1000), is a transapical, echo-guided system that delivers artificial chordae tendineae to re-suspend prolapsed mitral valve leaflets under real-time transesophageal echocardiography (TEE) guidance. The DS1000 received CE market clearance in December 2012 and carries an MR Conditional designation for 1.5T and 3.0T MRI scanning. In the United States the device remains investigational, with FDA IDE approval supporting ongoing clinical work including the RECHORD randomized trial.
The company is advancing a second-generation transcatheter platform, the NeoChord NeXuS System, which uses a transfemoral/transseptal approach for a less invasive procedure than the transapical DS1000. NeXuS completed first-in-human use in October 2021 with positive 30-day results, received FDA approval for an Early Feasibility Study, and won the CRT 2022 Best Innovation Competition. Supporting programs include ConsultConnect and ConnectCARD for clinical consultation, plus the AcChord post-market registry. The portfolio is anchored by registered trademarks (NEOCHORD, DS1000, RECHORD, NEOCHORD CONSULTCONNECT, CONNECTCARD, ACCHORD, ULTRACHORD) and a patent estate associated with the leadership team. By October 2016, more than 500 patients had been treated globally with DS1000, with follow-up data on 127 patients out to two years presented at EACTS.
NeoChord sells Class III medical hardware directly to hospitals and cardiac surgery centers through an enterprise field sales motion, supported by key opinion leader engagement, clinical trial programs, and presence at medical conferences. The company holds NUB Status 1 in Germany, providing favorable reimbursement conditions for the procedure. Geographic reach spans the United States, Europe (Germany, Poland), and Asia (China, with the first procedures completed in September 2018). The company has 11–50 employees, has raised over $90 million across multiple financing rounds including a $32 million Series D, and operates under CEO Todd Berg, who joined in September 2023 after prior roles as founder/CEO of Torax Medical (acquired by Johnson & Johnson) and CEO of Metavention.
NeoChord firmographics
Firmographics- Name
- NeoChord
- Legal name
- NeoChord, Inc.
- Website
- https://neochord.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeoChord is a privately held medical device company developing beating-heart mitral valve repair systems. Its CE-marked DS1000 and investigational NeXuS transcatheter platform deliver artificial chordae under echo guidance to treat degenerative mitral regurgitation at cardiac surgery centers.
- Ownership category
- akta.pro rank
NeoChord industry classification
Industry- Product category
- Mitral Valve Repair Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
- akta.pro secondary industry
- Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)
Keywords
Where NeoChord is headquartered
LocationHeadquarters
- HQ city
- Saint Louis Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeoChord business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales: NeoChord generates revenue through the sale of its NeoChord Artificial Chordae Delivery System (DS1000) and related products to hospitals and cardiac surgery centers. The company has received CE market clearance (December 2012) and FDA IDE approval for clinical trials in the US.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
NeoChord product offering
Product offeringCore offering
NeoChord develops and sells Class III medical devices for beating heart mitral valve repair, primarily the NeoChord Artificial Chordae Delivery System (DS1000), a transapical, echo-guided system that implants artificial chordae tendineae to treat degenerative mitral valve regurgitation without cardiopulmonary bypass. The company is also developing the next-generation NeXuS transcatheter transseptal chordal repair system for a less invasive approach, and operates the ConsultConnect clinical consultation program to support implanting physicians.
Product overview
NeoChord is a medical technology company with a focused product portfolio centered on mitral valve repair. The core offerings consist of two generations of chordal repair systems: the established DS1000 (transapical approach, CE marked in 2012) for beating heart mitral valve repair, and the newer transcatheter NeXuS System (transseptal approach, investigational) for less invasive procedures. Both products restore mitral valve function by implanting artificial chordae to support prolapsing valve leaflets. The portfolio also includes the ConsultConnect service program for clinical consultation support.
Differentiator
Problem solved
Functional benefit
Brands
- NeoChord DS1000: Artificial Chordae Delivery System for mitral valve repair
- NeoChord NeXuS
- NeoChord ConsultConnect
- ConnectCARD
- RECHORD
Products and services
- NeoChord Artificial Chordae Delivery System (DS1000) A transapical, echo-guided Class III medical device that delivers artificial chordae tendineae to repair degenerative mitral valve regurgitation on a beating heart without cardiopulmonary bypass. Indicated for patients with moderate to severe degenerative mitral valve regurgitation caused by elongated or ruptured chordae tendineae, and sold to hospitals and cardiac surgery centers. CE marked since December 2012; in the U.S. limited to investigational use under FDA IDE.
- NeoChord NeXuS Transcatheter Transseptal Mitral Chordal Repair System A transcatheter, transseptal catheter-based mitral chordal repair system designed to enable a less invasive approach to mitral valve repair compared to the transapical DS1000. The system received FDA approval for an Early Feasibility Study in the U.S. with Dr. Martin B. Leon serving as Executive Chair, and achieved first-in-human clinical results in October 2021.
- NeoChord ConsultConnect (including ConnectCARD) A medical consultation and clinical support service program related to delivery of artificial chordae tendineae for treatment of mitral insufficiency, providing healthcare professionals with access to NeoChord's clinical support, training, and expertise for the DS1000 and NeXuS procedures.
Quantifiable outcome
- 500+ patients treated globally with DS1000 system
- +2 more outcomes
Companies that use NeoChord
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
NeoChord technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NeoChord partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Skirball Center for Innovation at the Cardiovascular Research FoundationcoreNeoChord announced a research collaboration with the Skirball Center for Innovation at the Cardiovascular Research Foundation in January 2018. This collaboration supports the development and validation of NeoChord's mitral valve repair technologies through rigorous clinical research programs.
Scale indicators5 records
NeoChord competitors and assessment
Company assessmentMarket position
Key highlights7 records
Customer concentration
NeoChord social profiles
Digital presenceNeoChord compliance and trust
Trust signalCompliance2 records
NeoChord financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeoChord leadership team
Management profileNumber of profiles
Profiles8 records
NeoChord funding detail
Funding detailFunding overview
Funding rounds13 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeoChord M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeoChord
What does NeoChord do?
NeoChord develops and sells Class III medical devices for beating heart mitral valve repair, primarily the NeoChord Artificial Chordae Delivery System (DS1000), a transapical, echo-guided system that implants artificial chordae tendineae to treat degenerative mitral valve regurgitation without cardiopulmonary bypass. The company is also developing the next-generation NeXuS transcatheter transseptal chordal repair system for a less invasive approach, and operates the ConsultConnect clinical consultation program to support implanting physicians.
Is NeoChord a public or private company?
NeoChord is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeoChord founded?
NeoChord was founded in 2007. It employs 11 to 50 people.
Where is NeoChord based?
NeoChord is headquartered in Saint Louis Park, United States, in the North America region.
How does NeoChord make money?
One revenue line is on record: medical Device Sales.
Does NeoChord have an API?
No public API is recorded for NeoChord.
What industry is NeoChord in?
NeoChord's product category is Mitral Valve Repair Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 339112 and its SIC code is 3841.